COVID-19: from basic science to therapeutics
SARS-CoV-2, the causative agent of COVID-19, emerged in December 2019 and resulted in a global pandemic with more than 1.8 million deaths. A worldwide effort has been undertaken to assess the key drivers of COVID-19 pathology, identify therapeutic targets and boost vaccine development. To date, two vaccines have been FDA approved and more are undergoing testing. COVID-19 treatment options remain limited. Highly potent human monoclonal antibodies against SARS-CoV-2 are emerging as potential therapeutics for COVID-19 but clinical trials are still ongoing. Here we present a collection of articles published in JEM highlighting the latest findings on potential drivers of COVID-19 pathology, therapeutic targets and neutralizing antibodies.
Image © 2020 Veras et al.